Form 4: Enanta Pharmaceuticals' Chief Medical Officer Rottinghaus Sells Shares
SEC Form 4 Filing
Chief Medical Officer Scott T. Rottinghaus of Enanta Pharmaceuticals executed multiple transactions involving the sale and exercise of common stock and stock options between July 11 and July 15, 2024.
Summary
- Scott T. Rottinghaus, the Chief Medical Officer of Enanta Pharmaceuticals, reported changes in beneficial ownership.
- On July 11, 2024, he sold 4,299 shares of common stock at a weighted average price of $15.07.
- On July 12, 2024, he sold 2,271 shares of common stock at a weighted average price of $15.04.
- On July 15, 2024, he exercised a stock option for 5,375 shares at $8.99 and sold those shares at a weighted average price of $17.08.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted in March 2024.
- Following these transactions, Rottinghaus directly owns 21,717 shares of common stock and holds options for 80,625 shares.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency regarding insider transactions.
- The Rule 10b5-1 trading plan is a common tool used by executives to sell shares while avoiding accusations of insider trading, similar to practices at companies like Pfizer or Merck.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The impact on employees, customers, suppliers, and creditors is likely negligible.
Key Dates
| Date | Description |
|---|---|
| March 2024 | The reporting person adopted a Rule 10b5-1 trading plan. |
| November 22, 2023 | Date of grant for the stock option, representing a right to purchase a total of 86,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant. |
| 07/11/2024 | Rottinghaus sold 4,299 shares of common stock. |
| 07/12/2024 | Rottinghaus sold 2,271 shares of common stock. |
| 07/15/2024 | Rottinghaus exercised stock options for 5,375 shares and sold them. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.